Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy HMPL-A830 outside Greater China, with HCM receiving $110 million upfront and potential milestone payments up to $1.185 billion. This deal significantly boosts HCM's future revenue prospects and led to a positive market reaction, raising the stock price to $14.12. Other analysts also reaffirmed Buy ratings, signaling strong confidence in HCM's growth potential.
Duluth Holdings reported a strong Q2 earnings per share (EPS) of $0.50, far exceeding the consensus estimate of -$0.01, largely due to $0.44 per share from tariff refunds. Revenue reached $121.39 million, beating estimates but declining from the prev...
Estée Lauder Companies recently appointed new brand leaders, signaling strategic shifts in its competitive beauty market. An insider executive sold 7,766 shares worth over $802,000, leaving no remaining holdings. The company shows a high P/E ratio of...
HUTCHMED's shares surged 17.77% after announcing a major licensing deal with GSK for its preclinical cancer drug HMPL-A830. GSK gets exclusive rights outside Greater China, paying $110 million upfront plus up to $1.295 billion in milestone payments. ...
Genesco reported second-quarter earnings that surpassed analyst expectations, with an EPS loss of $0.83 versus the estimated loss of $1.37 per share. Although revenue fell 3% year-over-year to $529.86 million, the company improved its adjusted gross ...
Samsara Inc. will release its Q3 2026 earnings on September 3 after market close, with analysts expecting an EPS of $0.16 and revenue around $483 million. The company has a strong record of beating earnings estimates, with a 41.4% average surprise in...
